Different drug-resistant influenza A(H3N2) variants in two immunocompromised patients treated with oseltamivir during the 2011-2012 influenza season in Italy

Journal of Clinical Virology

Volumn 58, Issue 1, 2013, Pages 132-137

  Piralla, A ^a   Gozalo Marguello M ^b   Fiorina, L ^a   Rovida, F ^a   Muzzi, A ^a   Colombo, A A ^a   Alessandrino, P E ^a   Baldanti, F ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Del247 250; E119V; Influenza; N294S; Oseltamivir treated patients; R292K

Indexed keywords

OSELTAMIVIR; SIALIDASE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; FOLLOW UP; GENE DELETION; GENE SEQUENCE; HEMATOPOIETIC STEM CELL; HOSPITAL PATIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; INFLUENZA A (H3N2); INFLUENZA VIRUS A H3N2; ITALY; LUNG LAVAGE; MALE; NUCLEOTIDE SEQUENCE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSPECTIVE STUDY; VIRAL CLEARANCE; VIRUS LOAD; VIRUS SHEDDING;

EID: 84881546514     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.06.003     Document Type: Article

References (32)

1. Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP), 2011. Morb Mortal Wkly Rep 2011, 60:1128-1132.
2. Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the advisory committee on immunization practices (ACIP), 2011. Morb Mortal Wkly Rep 2011, 60:1-24.
3. Kim C.U., Lew W., Williams M.A., Liu H., Zhang L., Swaminathan S., et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997, 119:681-690.
4. von Itzstein M., Wu W.Y., Kok G.B., Pegg M.S., Dyason J.C., Jin B., et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363:418-423.
5. Colman P.M., Varghese J.N., Laver W.G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983, 303:41-44.
6. Richard M., Ferraris O., Erny A., Barthélémy M., Traversier A., Sabatier M., et al. Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir. Antimicrob Agents Chemother 2011, 55:2942-2952.
7. Gubareva L.V., Robinson M.J., Bethell R.C., Webster R.G. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997, 71:3385-3390.
8. Tai C.Y., Escarpe P.A., Sidwell R.W., Williams M.A., Lew W., Wu H., et al. Characterization of human influenza virus variants selected in vitro in the presence of neuraminidase inhibitor GS4071. Antimicrob Agents Chemother 1998, 42:3234-3241.
9. Hurt A.C., Ho H.T., Barr I. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors. Expert Rev Antiinfect Ther 2006, 4:795-805.
10. Abed Y., Baz M., Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 2006, 11:971-976.
11. Ferraris O., Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol 2008, 41:13-19.
12. Sheu T.G., Deyde V.M., Garten R.J., Klimov A.I., Gubareva L.V. Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing. Antiviral Res 2010, 85:354-360.
13. Thorlund K., Awad T., Boivin G., Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 2011, 11:134.
14. WHO Influenza A(H1N1) virus resistance to oseltamivir - 2008/2009 influenza season, northern hemisphere 18 March 2009, http://www.who.int/influenza/resources/documents/H1N1webupdate20090318_ed_ns-pdf [accessed 27.06.12].
15. World Health Organization Influenza virus activity in the world 25 May 2012, http://www.who.int/influenza/gisrs_laboratory/updates/summaryreport/en/index.html [accessed 20.06.12].
16. ECDC Influenza virus characterization - summary Europe March 2012, http://ecdc.europa.eu/en/publications/Publications/1204-TED-CNRL-report.pdf [accessed 27.06.12].
17. World Health Organization Recommended composition of influenza virus vaccine for use in the 2012-2013 northern hemisphere influenza season February 2012, http://www.who.int/influenza/vaccines/virus/recommendations/201202_recommendation.pdf [accessed 27.06.12].
18. World Health Organization Review of the 2011-2012 winter influenza season, northern hemisphere 2013, http://www.who.int/wer/2012/wer8724.pdf [accessed 13.07.12].
19. World Health Organization Summary of the 2011-2012 influenza season in the WHO European region 2013, http://www.euro.who.int/__data/assets/pdf_file/0008/168866/Season-overview-2011-2012_9jul-2012_FINAL.pdf [accessed 16.07.12].
20. WHO CDC protocol of realtime RTPCR for influenza A (H1N1) 2013, http://www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR_SwineH1Assay-2009_20090430.pdf [accessed 20.06.09].
21. Tamura K., Peterson D., Peterson N., Stecher G., Nei M., Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011, 28:2731-2739.
22. Lee N., Chan P.K., Hui D.S., Rainer T.H., Wong E., Choi K.W., et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009, 200:492-500.
23. Li C.C., Wang L., Eng H.L., You H.L., Chang L.S., Tang K.S., et al. Correlation of pandemic (H1N1) 2009 viral load with disease severity and prolonged viral shedding in children. Emerg Infect Dis 2010, 16:1265-1272.
24. Li I.W., Hung I.F., To K.K., Chan K.H., Wong S.S., Chan J.F., et al. The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. Chest 2010, 137:759-768.
25. Ruiz-Carrascoso G., Casas I., Pozo F., González-Vincent M., Pérez-Breña P. Prolonged shedding of amantadine- and oseltamivir-resistant influenza A(H3N2) virus with dual mutations in an immunocompromised infant. Antivir Ther 2010, 15:1059-1063.
26. Baz M., Abed Y., McDonald J., Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006, 43:1555-1561.
27. Campanini G., Piralla A., Rovida F., Puzelli S., Facchini M., Locatelli F., et al. First case in Italy of acquired resistance to oseltamivir in an immunocompromised patient with influenza A/H1N1v infection. J Clin Virol 2010, 48:220-222.
28. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364:759-765.
29. Okomo-Adhiambo M., Demmler-Harrison G.J., Deyde V.M., Sheu T.G., Xu X., Klimov A.I., et al. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother 2010, 54:1834-1841.
30. Memoli M.J., Hrabal R.J., Hassantoufighi A., Jagger B.W., Sheng Z.M., Eichelberger M.C., et al. Rapid selection of a transmissible multidrug-resistant influenza A/H3N2 virus in an immunocompromised host. J Infect Dis 2010, 201:1397-1403.
31. Abed Y., Baz M., Boivin G. A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus. J Infect Dis 2009, 199:180-183.
32. Gulati U., Hwang C., Venkatramani L., Gulati S., Stray S.J., Lee J.T., et al. Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98). J Virol 2002, 76:12274-12280.